“Epilepsy Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Epilepsy Market.
The Epilepsy Pipeline report embraces in-depth commercial, regulatory, and Epilepsy clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Epilepsy drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Epilepsy Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for Epilepsy treatment and the aggregate therapies developed by major pharma companies.
It accesses the different Epilepsy therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the major Epilepsy companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the Epilepsy drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Epilepsy therapeutic market.
Epilepsy Therapeutics Landscape
There are approx. 75+ key companies are developing therapies for Epilepsy. Currently, SK Life Science is leading the therapeutics market with its Epilepsy drug candidates in the most advanced stage of clinical development.
Epilepsy Companies Actively Working in the Therapeutic Market Include:
UCB
SK Life Science
Stoke Therapeutics
Xenon Pharmaceuticals
Epygenix
Bright Minds Biosciences
Neurona Therapeutics
Cevevel Therapeutics
PTC Therapeutics
Addex Pharmaceuticals
Equilibre Biopharmaceuticals B.V.
ES Therapeutics Australia Pty Ltd
Overseas Pharmaceuticals
Anavex Life Sciences
Eliem Therapeutics
Ovid Therapeutics
CAMP4 Therapeutics
LifeSplice
Virpax Pharmaceuticals
Neuroene Therapeutics
And Many Others
Emerging and Marketed Epilepsy Drugs Covered in the Report Include:
ZX008 (Fenfluramine Hydrochloride): UCB
Cenobamate: SK Life Science, Inc.
STK-001: Stoke Therapeutics
EPX-100: Epygenix
NRTX-1001: Neurona Therapeutics
BMB-101: Bright Minds Biosciences
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Epilepsy Companies Working in the Market @
https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight
Analysis of Emerging Epilepsy Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued and inactive candidates
Route of Administration
Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Molecule Type
Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Learn How the Epilepsy Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Epilepsy Treatment Patterns
4. Epilepsy – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Epilepsy Late Stage Products (Phase-III)
7. Epilepsy Mid-Stage Products (Phase-II)
8. Epilepsy Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Epilepsy Discontinued Products
13. Epilepsy Product Profiles
14. Major Epilepsy Companies in the Market
15. Key Products in the Epilepsy Therapeutics Segment
16. Dormant and Discontinued Products
17. Epilepsy Unmet Needs
18. Epilepsy Future Perspectives
19. Epilepsy Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Familial Hypercholesterolemia Market
“Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Familial Hypercholesterolemia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Familial Hypercholesterolemia market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Anuj RawatEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
